Evaluation of Safety and Efficacy of IPL Presets for Cutaneous Lesions
NCT ID: NCT05630690
Last Updated: 2023-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
20 participants
INTERVENTIONAL
2023-10-04
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Following the SMART Camera analysis, the system will suggest treatment presets. The physician will decide whether to use the treatment presets recommended by the AI system or modify them, based on the safety and efficacy of the suggested treatment presets.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IPL with smart diagnostic handpiece
Standard IPL module which has FDA clearance (K083733) for a wide range of indications including vascular and pigmented lesions. The Universal IPL handpiece (HP) operates at a spectrum of 400-1,200 nm with 7 different cut-off filters and 2 different notch filters that can be easily inserted into the handpiece to treat different conditions.
The SMART Camera is a novel add-on skin diagnostic (SD) tool. The SD module includes a proprietary spectral camera embedded in a handpiece, and proprietary computer vision-based algorithms designed to process the spectral information and to determine the skin attributes and optimal treatment IPL preset.
IPL with smart diagnostic handpiece
treatment with IPL following diagnostic with SMART system
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IPL with smart diagnostic handpiece
treatment with IPL following diagnostic with SMART system
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Fitzpatrick skin type I-V
3. Presence of visible textural lesions including but not limited to:
1. Lentigines
2. Age spots / Telangiectasia (Photoaging treatment)
3. Rosacea (Erythematotelangiectatic rosacea and papulopustular rosacea)
4. Telangiectasia
4. Patients should have at least 3 treatment areas of the following: right cheek, left cheek, forehead, nose, chin, or upper/lower décolletage.
5. Able to read, understand and provide written Informed Consent.
6. Able and willing to comply with the treatment/follow-up schedule and requirements.
7. Willing to have digital photographs taken of all of the treatment areas before, during, and after the treatment.
8. Willing to refrain from using any prescription or over-the-counter topical creams used for the treatment of veins or pigmented lesions in the treatment area during the study period.
9. Willing to protect and/or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher in the treatment area, every day for the duration of the study.
10. Agree not to undergo any other procedure(s) in the same treatment areas during the study.
11. Women of child-bearing age are required to be using a reliable method of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, NuvaRing, partner with vasectomy, or abstinence) at least 1 month prior to first treatment and throughout the course of the study.
Exclusion Criteria
2. Fitzpatrick skin type VI.
3. Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding.
4. Exposure to the sun or artificial tanning during 3-4 weeks prior to treatment. Any remaining suntan, sunburn, or artificial tanning products.
5. Active infections in the treatment area.
6. Dysplastic nevi.
7. Significant concurrent skin conditions or any inflammatory skin conditions.
8. Active cold sores, open lacerations, or abrasions in the treatment area.
9. Chronic or cutaneous viral, fungal or bacterial diseases.
10. Treatment should not be attempted on patients with a history or concurrent condition of skin cancer or pre-cancerous lesions in the treatment area
11. Tattoos in the treatment area.
21 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Emek Medical Center
OTHER
Lumenis Be Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lumenis Be Ltd.
Yokneam Illit, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Rula Masoud
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LUM-ABU-SMRT-22-02
Identifier Type: -
Identifier Source: org_study_id